Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03948490 · ClinicalTrials.gov registry record · NA
Rehabilitation and Longitudinal Follow-up of Cognition in Adult Lower Grade Gliomas
A NA study of Low Grade Glioma, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- NA
- Development phase
- 97
- Enrollment target
- 1
- Study location
NCT03948490: Recruiting NA study of Low Grade Glioma, sponsored by University of California, San Francisco.
NCT03948490 is a NA study of Low Grade Glioma that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 97 participants, below the 110-participant average among 23 other Low Grade Glioma trials with a reported enrollment target (12% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03948490, a NA study of Low Grade Glioma, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- NA
- Development phase
- 97 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients with glial brain tumors have increasingly improved outcomes, with median survival of 5-15 years. However, the treatments, including surgery, radiation, and chemotherapy, often lead to impaired attention, working memory, and other cognitive functions. These cognitive deficits frequently have significant impact on patient quality of life. Although currently, there is no established standard of care to treat cognitive deficits in brain tumor patients, standard cognitive rehabilitative treatments have been developed for those with traumatic brain injury and stroke. However, the feasibility and efficacy of these cognitive treatments in individuals with brain tumors remains unclear.
Primary Outcome
The intervention will be considered feasible for a larger-scale efficacy study if greater than 80% of the subjects complete the intervention. Patients will be replaced if they drop out of the intervention (either by declining their first follow-up visit for Cohort 1 in-person rehab; declining to participate in the Cohort 2 ReMind intervention; or by texting the word "STOP" in the Cohort 3 short message service (SMS) texting intervention)) within the first 14 days. These patients will be replaced
Conditions Studied
Interventions
- DEVICE ReMind iPad app
- DEVICE Healthy SMS texting
- BEHAVIORAL In-person cognitive rehabilitation
- BEHAVIORAL Telehealth cognitive rehabilitation
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2019-06-07 |
| Est. Completion | 2026-03-31 |
| Phase | NA |
What NCT03948490 shows while recruiting
NCT03948490 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 97 participants, a relatively small participant target, below the 110-participant average among 23 other Low Grade Glioma trials with a reported enrollment target (12% lower).
The record links to 1 condition, with Low Grade Glioma appearing as the primary indexed condition, and to 4 interventions - of which ReMind iPad app is the first listed.
NCT03948490 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03948490 about?
NCT03948490 is a clinical study titled "Rehabilitation and Longitudinal Follow-up of Cognition in Adult Lower Grade Gliomas". Patients with glial brain tumors have increasingly improved outcomes, with median survival of 5-15 years. However, the treatments, including surgery, radiation, and chemotherapy, often lead to impaired attention, working memory, and other cognitive functions. These cognitive deficits frequently have...
What is the current status of trial NCT03948490?
This trial is currently recruiting. It is a NA study. The enrollment target is 97 participants. The study started on 2019-06-07. Estimated completion is 2026-03-31.
What conditions does trial NCT03948490 study?
This clinical trial studies the following conditions: Low Grade Glioma.
What interventions are being tested in trial NCT03948490?
The interventions under investigation include: ReMind iPad app (DEVICE), Healthy SMS texting (DEVICE), In-person cognitive rehabilitation (BEHAVIORAL), Telehealth cognitive rehabilitation (BEHAVIORAL).
Who is sponsoring clinical trial NCT03948490?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03948490 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Low Grade Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03948490's enrollment target sits among peer trials
97 12th of 23 higher than 12 of 23 other Low Grade Glioma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Low Grade Glioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
HOBSCOTCH-CA (HOme-Based Self-management and COgnitive Training CHanges Lives in Brain CAncer)
RECRUITING · NA
-
Mind-Body Intervention in Glioma Couples
ACTIVE NOT RECRUITING · NA
-
Proton Radiation Therapy for Gliomas
ACTIVE NOT RECRUITING · NA
-
A Vaccine Trial for Low Grade Gliomas
RECRUITING · Phase 2
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04140487 · 97 participants · Phase 1
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
- NCT04196413 · 97 participants · Phase 1
GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)
- NCT05223816 · 97 participants · Phase 2
An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
- NCT06076538 · 97 participants
PET/MR for Characterization of Renal Masses (RMs)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI